The European Liver Transplant Registry (eltr): Improved Survival Outcomes in De Novo Liver Transplantation with Tacrolimus Prolonged Release (Advagraf).

Retrospective analysis of LTx pts receiving de novo ADVAGRAF (ADV; n=505) or tacrolimus immediate release (BD; n=4299) in the ELTR over 3 years. Factors influencing graft/pt survival were identified using uni- and multivariate regression (p<0.05). Differences between ADV/Tac BD were assessed by KM analysis. Comparable baseline demographics. Overall graft/pt survival: 73% and 77%. Univariate analysis identified non-ADV as a significant risk factor for poor graft/pt survival (p=0.0004, p=0.006). Significance was confirmed by multivariate analysis for graft survival (table). KM analysis demonstrated significantly improved graft/pt survival with ADV vs Tac BD over 3 years (graft: 82% vs 73%, p=0.0004; pt: 83% vs 76%, p=0.006).Table: No Caption available.A large observational study from the ELTR identified significant improvements in graft/pt survival with ADV vs Tac BD in de novo LTx over 3 years. DISCLOSURES:Adam, R.: Other, Astellas, Astellas supports ELTR. Karam, V.: Other, Astellas, Astellas supports ELTR. Delvart, V.: Other, Astellas, Astellas supports ELTR. Trunecka, P.: Other, Astellas, Advisory boards & received consultancy agreements, Pfizer, Speaker honorarium. Samuel, D.: Other, Astellas, Consultant fees and Astellas supports ELTR, Novartis, Consultant fees, Roche, Consultant fees. Bechstein, W.: Other, Astellas, Honoraria and served on advisory boards. Klempnauer, J.: Other, Astellas, Support, Novartis, Support, Roche, Support, Genzyme, Support, BMS, Support. Colledan, M.: Other, Novartis, Honorarium for advisory board. Muiesan, P.: Other, Novartis, One off honorarium for participating at ad board.